RP
BIO icon

Rowlandmiller & Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Rowlandmiller & Partners’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$161K Sell
550
-15
-3% -$4.25K 0.03% 167
2026
Q1 		$157K Hold
565
– – 0.03% 163
2025
Q4 		$171K Hold
565
– – 0.03% 160
2025
Q3 		$158K Sell
565
-95
-14% -$25.9K 0.03% 159
2025
Q2 		$159K Sell
660
-8
-1% -$1.89K 0.03% 155
2025
Q1 		$163K Sell
668
-185
-22% -$55.7K 0.03% 151
2024
Q4 		$280K Sell
853
-30
-3% -$10.2K 0.06% 130
2024
Q3 		$295K Sell
883
-95
-10% -$30.2K 0.06% 130
2024
Q2 		$267K Sell
978
-75
-7% -$21.8K 0.06% 127
2024
Q1 		$364K Sell
1,053
-18
-2% -$5.92K 0.08% 119
2023
Q4 		$346K Sell
1,071
-20
-2% -$6.27K 0.08% 117
2023
Q3 		$391K Sell
1,091
-136
-11% -$52.5K 0.1% 106
2023
Q2 		$465K Sell
1,227
-235
-16% -$95.6K 0.11% 105
2023
Q1 		$700K Sell
1,462
-255
-15% -$119K 0.17% 87
2022
Q4 		$725K Hold
1,717
– – 0.18% 84
2022
Q3 		$716K Buy
1,717
+65
+4% +$32.4K 0.19% 78
2022
Q2 		$818K Buy
1,652
+75
+5% +$39.1K 0.21% 73
2022
Q1 		$888K Buy
1,577
+240
+18% +$145K 0.21% 74
2021
Q4 		$1.01M Buy
1,337
+674
+102% +$504K 0.23% 72
2021
Q3 		$299K Sell
663
-674
-50% -$505K 0.1% 97
2021
Q2 		$861K Buy
1,337
+115
+9% +$70K 0.21% 79
2021
Q1 		$698K Buy
1,222
+293
+32% +$174K 0.18% 79
2020
Q4 		$542K Buy
+929
New +$529K 0.15% 87
2020
Q3 		– Sell
-663
Closed -$299K – 143
2020
Q2 		$299K Buy
+663
New +$293K 0.1% 97

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Rowlandmiller & Partners's BIO Position: Q2 2026 in Review

Rowlandmiller & Partners reduced its Bio-Rad Laboratories Class A (BIO) stake by 2.7% in Q2 2026, selling an estimated $4.25K and leaving 550 shares worth $161K. The position accounts for 0.03% of the portfolio, ranked #167.

Rowlandmiller & Partners first reported a position in BIO in Q2 2020 and has held it in 24 quarters since. The position peaked at $1.01M in Q4 2021. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Rowlandmiller & Partners held 550 shares of Bio-Rad Laboratories Class A worth $161K as of Q2 2026.
  • Rowlandmiller & Partners sold 15 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $4.25K.
  • Bio-Rad Laboratories Class A made up 0.03% of Rowlandmiller & Partners's portfolio in Q2 2026, its #167 holding.
  • Rowlandmiller & Partners first reported a position in Bio-Rad Laboratories Class A in Q2 2020 and has held it in 24 quarters since.
  • Rowlandmiller & Partners's Bio-Rad Laboratories Class A position peaked at $1.01M in Q4 2021.
  • 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Rowlandmiller & Partners's 13F filing for Q2 2026, filed 23 Jul 2026.